Skip to content

Antifungal susceptibility data-Outcome of fungal keratitis

To assess the outcome of fungal keratitis managed based on the antifungal susceptibility data

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/01/049162
Enrollment
50
Registered
2023-01-24
Start date
Unknown
Completion date
Unknown
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H171- Central corneal opacity

Interventions

Intervention1: changing of the antifungal: 1.Topical Natamycin 5% every half an hourly 2.Oral Ketoconzole 200 mg BD after ruling out associated Liver disease. 3.Atropine eye drop 1% three times a day

Sponsors

L V Prasad Eye Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a) Microbiologically proven fungal keratitis with confirmed and significant growth of fungus as per the criteria of significant growth. b) Size of ulcer ranging between 8mm without corneal perforation c) Patients willing to participate and follow up

Exclusion criteria

Exclusion criteria: a) Mixed infections; concomitant fungal, viral or Acanthamoeba infections b) Size of ulcer more than 8 mm c) Impending perforation or presence of corneal perforation at the time of presentation or limbal involvement d) Associated posterior segment involvement or endophthalmitis

Design outcomes

Primary

MeasureTime frame
BCVA, Healing time, Number of corneal ulcers responded on medical treatmentTimepoint: 2 weeks

Secondary

MeasureTime frame
Number of patients worsened and undergone therapeutic Penetrating keratoplasty (TPK) for worsening of infection.Timepoint: 2 weeks

Countries

India

Contacts

Public ContactDrBhupesh Bagga

L V Prasad Eye Institute

bhupesh@lvpei.org04068102515

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026